Genor Biopharma Releases Its Annual Results for 2020
- Written by Media Outreach
Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing
- NDA/BLA progress - GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) biosimilar) under Review
- Clinical development – Three products' registrational pivotal trails completed (GB226,GB221,GB242), GB491 (CDK...
Read more: Genor Biopharma Releases Its Annual Results for 2020